The most profitable SDG to date is SDG #3: "Good Health & Well Being" (vaccines / biotech / data).
https://www.gavi.org/our-alliance/global-health-development/sustainable-development-goals
https://www.gavi.org/our-alliance/global-health-development/sustainable-development-goals
www.gavi.org
Sustainable Development Goals
Learn about immunisation’s key role in achieving 14 of the 17 Sustainable Development Goals
I believe you’ll conclude what kind of conspiracy theory view of the world you hold by the time the first 3.5min of this interview is heard.
Very interesting indeed.
The interviewer, John Kirby, has a very good.
Best wishes
Mike
Dr Mike Yeadon
https://www.bitchute.com/video/uRkSUA3V5V2L/
Very interesting indeed.
The interviewer, John Kirby, has a very good.
Best wishes
Mike
Dr Mike Yeadon
https://www.bitchute.com/video/uRkSUA3V5V2L/
Bitchute
PERSPECTIVES ON THE PANDEMIC | EPISODE 23 | "2020: A PROPAGANDA MASTERPIECE" PART 3
In Episode 23, the third and final part of "2020: A Propaganda Masterpiece", Professor Mark Crispin Miller of New York University illustrates how the sudden overthrow of political freedom and bodily sovereignty, nominally triggered of necessity by the emergence…
This is an important paper & it’s importance rests on its findings utterly demolishing, once & for all, that “lockdowns” do not save lives, while applying hideous damage to everything we hold dear in life.
It obliterated the case for lockdowns, period.
Best wishes,
Mike
Dr Mike Yeadon
https://www.tandfonline.com/doi/full/10.1080/13571516.2021.1976051
It obliterated the case for lockdowns, period.
Best wishes,
Mike
Dr Mike Yeadon
https://www.tandfonline.com/doi/full/10.1080/13571516.2021.1976051
Taylor & Francis
Covid-19 Lockdown Cost/Benefits: A Critical Assessment of the Literature
An examination of over 100 Covid-19 studies reveals that many relied on false assumptions that over-estimated the benefits and under-estimated the costs of lockdown. The most recent research has sh...
LOCKDOWNS INCREASE TRANSMISSION OF RESPIRATORY VIRUSES, THEY DO NOT DECREASE CASES
"In the framework of this analysis, there is no evidence that more restrictive nonpharmaceutical interventions (‘lockdowns’) contributed substantially to bending the curve of new cases in England, France, Germany, Iran, Italy, the Netherlands, Spain or the United States in early 2020. By comparing the effectiveness of NPIs on case growth rates in countries that implemented more restrictive measures with those that implemented less-restrictive measures, the evidence points away from indicating that mrNPIs provided additional meaningful benefit above and beyond lrNPIs. While modest decreases in daily growth (under 30%) cannot be excluded in a few countries, the possibility of large decreases in daily growth due to mrNPIs is incompatible with the accumulated data.
The direction of the effect size in most scenarios points towards an increase in the case growth rate, though these estimates are only distinguishable from zero in Spain (consistent with nonbeneficial effect of lockdowns). Only in Iran do the estimates consistently point in the direction of additional reduction in the growth rate, yet those effects are statistically indistinguishable from zero.
While it is hard to draw firm conclusions from these estimates, they are consistent with a recent analysis that identified increased population-level transmission and cases in Hunan, China, during the period of stay-at-home orders, attributed to increased intra-household density and transmission.
In other words, it is possible that stay-at-home orders may facilitate transmission if they increase person-to-person contact where transmission is efficient such as closed spaces. "
https://onlinelibrary.wiley.com/doi/full/10.1111/eci.13484
"In the framework of this analysis, there is no evidence that more restrictive nonpharmaceutical interventions (‘lockdowns’) contributed substantially to bending the curve of new cases in England, France, Germany, Iran, Italy, the Netherlands, Spain or the United States in early 2020. By comparing the effectiveness of NPIs on case growth rates in countries that implemented more restrictive measures with those that implemented less-restrictive measures, the evidence points away from indicating that mrNPIs provided additional meaningful benefit above and beyond lrNPIs. While modest decreases in daily growth (under 30%) cannot be excluded in a few countries, the possibility of large decreases in daily growth due to mrNPIs is incompatible with the accumulated data.
The direction of the effect size in most scenarios points towards an increase in the case growth rate, though these estimates are only distinguishable from zero in Spain (consistent with nonbeneficial effect of lockdowns). Only in Iran do the estimates consistently point in the direction of additional reduction in the growth rate, yet those effects are statistically indistinguishable from zero.
While it is hard to draw firm conclusions from these estimates, they are consistent with a recent analysis that identified increased population-level transmission and cases in Hunan, China, during the period of stay-at-home orders, attributed to increased intra-household density and transmission.
In other words, it is possible that stay-at-home orders may facilitate transmission if they increase person-to-person contact where transmission is efficient such as closed spaces. "
https://onlinelibrary.wiley.com/doi/full/10.1111/eci.13484
Wiley Online Library
Assessing mandatory stay‐at‐home and business closure effects on the spread of COVID‐19
Background and Aims
The most restrictive nonpharmaceutical interventions (NPIs) for controlling the spread of COVID-19 are mandatory stay-at-home and business closures. Given the consequences of the...
The most restrictive nonpharmaceutical interventions (NPIs) for controlling the spread of COVID-19 are mandatory stay-at-home and business closures. Given the consequences of the...
Forwarded from Mike Yeadon
Scathing open letter to Canadian authorities!
Mike
Mike
Forwarded from Mike Yeadon
2021-10-04-LT-CPSA(1).pdf
998.2 KB
On Merck's Covid-19 drug, "the orally available prodrug form of
rNHC, molnupiravir (EIDD-2801 or MK-4482)".
Shuntai Zhou et al., "β-d-N4-hydroxycytidine Inhibits SARS-CoV-2
Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells,"
The Journal of Infectious Diseases 224, no. 3 (August 2021),
https://doi.org/10.1093/infdis/jiab247
"Due to their mechanism of action, mutagenic ribonucleoside analogs
could be metabolized by the host cell.. The concern would be that mutations in host DNA could contribute to the
development of cancer, or cause birth defects either in a developing
fetus or through incorporation into sperm precursor cells." ...
"It seems unlikely that a short course of therapy would spare the host
from this exposure because both RNA precursors that affect the virus
and DNA precursors that would affect the host pass through the common
ribonucleoside diphosphate intermediate."
rNHC, molnupiravir (EIDD-2801 or MK-4482)".
Shuntai Zhou et al., "β-d-N4-hydroxycytidine Inhibits SARS-CoV-2
Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells,"
The Journal of Infectious Diseases 224, no. 3 (August 2021),
https://doi.org/10.1093/infdis/jiab247
"Due to their mechanism of action, mutagenic ribonucleoside analogs
could be metabolized by the host cell.. The concern would be that mutations in host DNA could contribute to the
development of cancer, or cause birth defects either in a developing
fetus or through incorporation into sperm precursor cells." ...
"It seems unlikely that a short course of therapy would spare the host
from this exposure because both RNA precursors that affect the virus
and DNA precursors that would affect the host pass through the common
ribonucleoside diphosphate intermediate."
OUP Academic
β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
Abstract. Mutagenic ribonucleosides can act as broad-based antiviral agents. They are metabolized to the active ribonucleoside triphosphate form and concen
On Merck's Covid-19 drug, "the orally available prodrug form of
rNHC, molnupiravir (EIDD-2801 or MK-4482)".
"We previously showed that ?-D-N4-hydroxycytidine (rNHC) and its orally bioavailable prodrug, molnupiravir, acts as a broad-spectrum antiviral against coronaviruses in vitro and in vivo through lethal mutagenesis. Molnupiravir is currently in clinical trials for the treatment of SARS-CoV-2 infection. However, there are concerns that rNHC could be metabolized to dNHC and cause mutations in host cells.
rNHC showed a dose-dependent inhibition and mutagenic effect of SAR-CoV-2 in vitro. However, rNHC would be expected to be metabolized into the deoxynucleotide pool (by host RNR), resulting in DNA mutation of dividing mammalian cells. We demonstrated such mutagenic potential in a simple mammalian cell detection scheme. Molnupiravir has considerable potential as an orally bioavailable direct acting antiviral against SARS-CoV2 early in infection [Really..what about Ivermectin instead?], especially in high risk patients. However, clinical use should be carefully considered in light of its potential mutagenic effects on the host."
https://www.croiconference.org/abstract/rnhc-inhibits-sars-cov-2-in-vitro-but-is-mutagenic-in-mammalian-cells/
rNHC, molnupiravir (EIDD-2801 or MK-4482)".
"We previously showed that ?-D-N4-hydroxycytidine (rNHC) and its orally bioavailable prodrug, molnupiravir, acts as a broad-spectrum antiviral against coronaviruses in vitro and in vivo through lethal mutagenesis. Molnupiravir is currently in clinical trials for the treatment of SARS-CoV-2 infection. However, there are concerns that rNHC could be metabolized to dNHC and cause mutations in host cells.
rNHC showed a dose-dependent inhibition and mutagenic effect of SAR-CoV-2 in vitro. However, rNHC would be expected to be metabolized into the deoxynucleotide pool (by host RNR), resulting in DNA mutation of dividing mammalian cells. We demonstrated such mutagenic potential in a simple mammalian cell detection scheme. Molnupiravir has considerable potential as an orally bioavailable direct acting antiviral against SARS-CoV2 early in infection [Really..what about Ivermectin instead?], especially in high risk patients. However, clinical use should be carefully considered in light of its potential mutagenic effects on the host."
https://www.croiconference.org/abstract/rnhc-inhibits-sars-cov-2-in-vitro-but-is-mutagenic-in-mammalian-cells/
CROI Conference
RNHC INHIBITS SARS-CoV-2 IN VITRO BUT IS MUTAGENIC IN MAMMALIAN CELLS
We previously showed that ?-D-N4-hydroxycytidine (rNHC) and its orally bioavailable prodrug, molnupiravir, acts as a broad-spectrum antiviral against coronaviruses in vitro and in vivo through lethal mutagenesis. Molnupiravir is currently in clinical trials…
Take Vitamin D (2,000 IU minimum) in winter
The seasonal peaks of coronaviruses and of most respiratory diseases correlate with the troughs in the amounts of vitamin D in the human body. It can be deduced that respiratory viruses exploit vitamin D deficiencies. A comprehensive analysis of the correlation of vitamin D with incidence and outcomes of Covid19 disease was published by The Royal Society in December 2020.
The levels of UVB light at many latitudes during the winter months are not sufficient to allow the skin to produce optimal levels of vitamin D, and nutrition is unlikely to be enough to compensate for the lack of vitamin D from sunlight in Winter. For this reason the Monotti Protocol recommends a daily minimum level of vitamin D supplementation of 2,000 IU a day, and an optimal supplementation of 4,000 IU per day for an average sized adult with no contraindications in late Autumn, all of Winter and early Spring.
There is no requirement or need for supplementation in Spring, Summer and early Autumn for people who spend a good portion of daily time outdoors. This level of supplementation has been proved to reduce both the incidence and the severity of respiratory disease.
The Monotti Protocol For Keeping Society Open – No Place Without Spirit
https://nulluslocussinegenio.com/2021/03/23/the-monotti-protocol/
The seasonal peaks of coronaviruses and of most respiratory diseases correlate with the troughs in the amounts of vitamin D in the human body. It can be deduced that respiratory viruses exploit vitamin D deficiencies. A comprehensive analysis of the correlation of vitamin D with incidence and outcomes of Covid19 disease was published by The Royal Society in December 2020.
The levels of UVB light at many latitudes during the winter months are not sufficient to allow the skin to produce optimal levels of vitamin D, and nutrition is unlikely to be enough to compensate for the lack of vitamin D from sunlight in Winter. For this reason the Monotti Protocol recommends a daily minimum level of vitamin D supplementation of 2,000 IU a day, and an optimal supplementation of 4,000 IU per day for an average sized adult with no contraindications in late Autumn, all of Winter and early Spring.
There is no requirement or need for supplementation in Spring, Summer and early Autumn for people who spend a good portion of daily time outdoors. This level of supplementation has been proved to reduce both the incidence and the severity of respiratory disease.
The Monotti Protocol For Keeping Society Open – No Place Without Spirit
https://nulluslocussinegenio.com/2021/03/23/the-monotti-protocol/
No Place Without Spirit
The Monotti Protocol For Keeping Society Open
The Monotti Protocol, 2021 The Monotti Protocol aims to be at the same time extremely simple yet extremely effective. It consists of three main epidemic or pandemic control approaches, to be implem…